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ABSTRACT  Tumor-promoting  phorbol esters have been reported to greatly increase  plasmin- 
ogen  activator  (PA) activity  produced  in  numerous  cell  types.  Many of these  studies  have 
employed a widely used fibrinolysis  assay for PA activity that involves  large-scale  dilution  of 
cell lysates or conditioned  medium (CM) into buffer containing plasminogen and the plasmin 
substrate 1251-fibrin. This assay indicates that phorbol ester and the mitogens epidermal growth 
factor (EGF) and thrombin all stimulate secretion of PA activity in our human foreskin fibroblast 
cultures.  However, these effects are not observed  in a modified  fibrinolysis  assay employing 
undiluted  conditioned  culture  medium  unless  the  medium  is  first  treated  at  pH  3,  which 
inactivates the secreted  protease inhibitor,  protease nexin (PN). Moreover, a direct assay for 
plasminogen activator activity based on cleavage of 12Sl-plasminogen indicates that conditioned 
culture  medium  contains  little  if  any  active  plasminogen  activator  either  before  or  after 
treatment of the cultures with phorbol ester or EGF. Phorbol ester and mitogens do stimulate 
secretion  of (a) an  inactive  PA that can  be activated  by plasmin  and  (b)  PN, which  inhibits 
both  the  activated  form  of the  PA and  plasmin.  Secretions  of the  inactive  PA and  PN  are 
further correlated  in that release of both is stimulated  most by phorbol ester,  somewhat less 
by EGF, and least by thrombin. Significantly,  these effects are not accompanied  by increases 
in total  protein  secretion.  We  propose that fibroblasts  secrete  PA in an  inactive  form  in the 
presence of PN to confine  PA activity to an as yet undefined location or event. 
Numerous investigators have reported that treatment of cell 
cultures with tumor-promoting phorbol esters or growth fac- 
tors greatly increases cellular production of plasminogen ac- 
tivator  (PA)'  activity (1-7).  These  findings  are  intriguing 
because elevated  PA  activity  produced  by  malignant  cells 
contributes to several aberrant properties of these cells,  in- 
cluding altered morphology (8) and the abilities to hydrolyze 
fibrin clots (9) and grow in soft agar (10).  Recently, a widely 
used PA assay that has been employed in a  number of the 
phorbol ester/growth factor studies has been shown to artifac- 
tually activate latent PA in culture medium conditioned by 
several different cell types (1 l,  12). This assay involves dilu- 
tion of ceil-conditioned medium or cell lysates into ~25I-fibrin- 
coated wells containing Tris. Cl buffer and plasminogen. PA 
' Abbreviations used in this paper:  CM, conditioned medium; EGF, 
epidermal growth factor; HF, human foreskin fibroblasts; PA, plas- 
minogen activator; and PN, protease nexin. 
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activity is measured by the extent of plasmin-mediated hy- 
drolysis of '25I-fibrin.  Unfortunately, small amounts of plas- 
min, which can contaminate plasminogen preparations, acti- 
vate inactive PA  secreted by several types of cells (12-14). 
The  absence  of NaC1  in  the  assay  buffer  also  apparently 
destabilizes inactive secreted PA (l 1). Furthermore, dilution 
of conditioned medium or cell lysates reduces the concentra- 
tions  of fibrinolytic inhibitors  that  may be  present.  These 
problems should prompt reexamination of PA activity in a 
number of systems. 
The present manuscript describes the influence of phorbol 
ester and growth factors on fibrinolytic regulation by normal 
human  foreskin  fibroblasts  (HF  cells).  We  have  recently 
shown that in unsupplemented serum-free culture these cells 
impose two kinds of negative control on  secreted PA (14). 
First, although HF cells release PA, it is in an inactive form. 
This material is similar or identical to a proenzyme form of 
the PA urokinase that has recently been purified from human 
323 tumor  cell-conditioned  medium  (12).  Both  the  urokinase 
proenzyme and HF cell PA are activated by plasmin, and are 
artifactually  activated  in  the  standard  '25I-fibrin  well assay. 
Second, HF cells also secrete the protease inhibitor, protease 
nexin (PN) (15), which inhibits activated HF cell plasminogen 
activator.  Below  we  present  evidence  that  neither  phorbol 
ester nor growth factors stimulate accumulation of active PA 
in HF cell culture medium.  However, these agents stimulate 
cellular release of both the plasmin-activatable PA and PN. 
MATERIALS  AND  METHODS 
Proteins:  Proteins were obtained from the  following sources: bovine 
serum albumin (BSA)  (Cohn fraction V), gelatin, and soybean trypsin inhibitor 
from Sigma Chemical Co.  (St. Louis, MO), fibrinogen from Calbiochem- 
Behring (La Julia, CA); pancreatic elastase, chymotrypsin, trypsin, and pan- 
creatic trypsin inhibitor from Worthington Biochemical Co. (Freehold, NJ); 
urokinase from Collaborative Research (Lexington, MA); mouse epidermal 
growth factor (EGF) was a gift from Patricia CorneAs (University of Kansas); 
human a-thrombin  originally purified in the laboratory of Roger Lundblad 
(University of North Carolina) was a gift from Louis Houston (University of 
Kansas); plasminogen was  purified from  outdated human  plasma by  the 
procedure of Deutsch and Mertz ( 16); plasmin was prepared as described by 
Dane and Reich (17) and was stored at 5"C in the presence of 50% glycerol. 
Human fibmblast PN (50,000 daltons) was purified from serum-free microcar- 
rier culture conditioned medium by beparin-Sepharose chromatography. The 
purification and characterization of PN will be presented later. 
Cell  Culture:  Human  foreskin fibmblasts (HF cells) were grown in 
Dulbecco's modified Eagle's medium (DME) containing antibiotics and 5% 
calf serum (M. A. Bioproducts, Walkersville,  MA) as previously  described (18). 
Quiescent cultures were prepared for experiments by seeding  2 x  10  -5 cells into 
35-ram diameter culture dishes (Falcon Plastics, Oxnard, CA) in 2 ml of the 
above serum-containing medium and allowing the cells to grow to confluence 
over 4-5 d.  The confluent cultures were rinsed, and incubated with DME 
containing 0.01% BSA ("serum-free medium").  Phorbol myristate acetate 
(Sigma Chemical Co.) and growth factors were diluted in DME and filter- 
sterilized before addition to cultures. 
Experimental Procedures:  Plasmin, plasminogen, and  thrombin 
were radioiodinated by incubation of 10 gg of protein with 0.3 mCi of Na 'zs1 
(Amersham, Arlington Heights, IL) in the presence of chloroglycoluril  (Pierce, 
Rockford, IL) and separated from unreacted '251 as previously described (15). 
Fibrinogen was iodinated as above, except that it was incubated in the iodina- 
tion reaction mixture at  1 mg/ml. Radioiodinated plasmin and plasminogen 
were stored at -80"C in the presence of 50% glycerol. 
Fibrinolysis assay of plasminogen activator (PA) activity in Tris-CI buffer 
was carried out as described by Loskutoff and Edgington (19). Assay of PA 
activity by cleavage  of '251-plasminogen  was carried out by the method of Dane 
and Reich (17) using modifications as described in Fig. 3. 
To measure the concentration of PN in conditioned culture medium, we 
assumed that PN and thrombin are present in equimolar amounts in thrombin- 
PN complexes (15), and determined the amount  of '2~I-thrombin that  was 
incorporated into SDS-stable 72-kdalton complexes when the labeled protease 
(0.2 t~g/ml)  was incubated with medium samples for 1 h at 37"C. '25I-thrombin 
in the complexes was resolved by SDS PAGE and quantitated in a gamma 
scintillation counter. SDS PAGE was carried out in 7% polyacrylamide gels 
according to the method of Weber and Osborn (20). Collagen secretion was 
assayed as described by Peterkofsky and Diegelmann (21). 
RESULTS 
Consistent with observations made on a  variety of other cell 
types, incubation of HF cells with phorbol ester dramatically 
increased cellular production  of PA activity as measured  by 
the standard  fibrinolysis assay of PA (Fig.  1  A). In the assay, 
50  ~l  of serum-free  cell-conditioned  culture  medium  (CM) 
was incubated with plasminogen in  1 ml Tris. C1 buffer inside 
'25I-fibrin-coated plastic wells. CM  from cultures treated  for 
l  d  with phorbol myristate acetate at  l0 ng/ml caused nearly 
complete hydrolysis of 'zsI-fibrin in the wells in 2  h, whereas 
only 5% of the '25I-fibrin was hydrolyzed in wells containing 
CM from untreated control cultures. In both cases fibrinolysis 
was mediated by cell-released PA activity because CM incu- 
bated  without  plasminogen  was  inactive  (data  not  shown). 
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FIGURE  1  Fibrinolytic activity of HF cell-conditioned media incu- 
bated with plasminogen under various conditions. Quiescent cul- 
tures of HF cells were incubated for 24 h with no supplement (C), 
EGF at 10 ng/ml (E), or phorbol myristate acetate at  10 ng/ml (P), 
and the conditioned culture media were assayed for plasminogen 
activator activity by three different protocols. In all cases the media 
were incubated in  '2sl-fibrin-coated wells containing plasminogen 
at 5 #g/ml. Plasminogen was added to each well in 50/A of 0.1  M 
Tris-CI buffer, pH 8.1. (A) the media were diluted 20-fold in 0.1 M 
Tris-CI buffer (pH 8.1) containing 0.1% gelatin, and 1-ml volumes 
of these mixtures were added to the wells. (B)  1-ml volumes of 
undiluted  media were added to  the wells.  (C)  the  media were 
preincubated at pH 3 for 2 h on ice. After raising the pH to 7.5, the 
assay was carried out as described for B. 
Fig.  1A  shows  that,  in  the  above  assay,  CM  from  cultures 
incubated  for  1 d  with  EGF also exhibited greatly increased 
PA activity, although  less than that  caused by phorbol  ester 
treatment. This stimulation is in accord with the finding that 
EGF  stimulated  secretion  of PA  by  3T3  cells  (22).  These 
increases  in  apparent  PA  activity  in  HF  cultures  did  not 
reflect increases in  cell mass or number  in phorbol  ester- or 
EGF-treated cultures. Those parameters increase significantly 
only after 2-3  d  of continuous treatment  (reference  18, and 
our unpublished data). 
The effects of phorbol  ester and EGF on PA activity were 
measured  using a  modification of the above assay.  Plasmin- 
ogen  was  added  to  undiluted  CM,  and  this  mixture  was 
incubated in the '25I-fibrin-coated wells. In this case, CM from 
control, EGF-, and phorbol ester-treated cultures all contained 
similar,  barely  detectable  levels  of  PA  activity  (Fig.  1B). 
Although  the  observed  fibrinolysis  was  significantly  above 
background,  this  represented  far  less  PA  activity than  was 
present in even control CM in the standard fibrinolysis assay. 
Note  that  the  latter  assay  involved  a  20-fold  dilution  of 
secreted PA and only a  2-h fibrinolysis incubation time (Fig. 
I A), yet in  all cases  it detected  greater  fibrinolysis than  oc- 
curred over  16  h  in the assay employing undiluted CM (Fig. 
1 B). The decreased fibrinolytic activity observed in the assay 
employing undiluted  CM  was  not  surprising  in  view of the 
presence of NaCI in CM (1 I). However, this did not explain 
why there  was not more  PA activity in  undiluted  CM  from 
phorbol ester- or EGF-treated cultures than in undiluted CM 
from  untreated  cultures.  Because  HF  cells  secrete  the  PA 
inhibitor,  PN  (14),  the lack of difference between undiluted 
CM  could be caused  by elev~tted levels of PN  in  CM  from 
phorbol ester or EGF-treated cultures. 
Stimulation of PN Secretion  by Phorbol Ester and 
Growth Factors 
PN  is  inactivated  by  incubation  at  pH3  (14).  To  check 
whether  the  similarly  low  levels  of fibrinolysis-stimulating activity in CM from control, phorbol ester- and EGF-treated 
cultures could have resulted  from differential  cellular  secre- 
tion  of PN,  we  acid-treated  CM  and  then  measured  PA 
activity in undiluted CM samples.  As shown in Fig.  1 C, acid 
treatment increased fibrinolysis  stimulated by undiluted CM 
from both control and treated cultures.  Furthermore,  acid- 
treated CM from cultures incubated with phorbol ester exhib- 
ited far more PA activity than acid-treated CM from untreated 
cultures.  Acid-treated CM from cultures incubated with EGF 
stimulated an intermediate level of fibrinolytic activity.  The 
relationship  between  these  activities  is  approximately  the 
same as when the CM samples were  diluted  20-fold  in the 
standard fibrinolysis assay (compare Fig.  l, A and C). 
Because the above data suggest that phorbol ester and EGF 
may stimulate PN secretion,  we measured PN levels in CM 
treated with these agents. Additionally, we checked CM from 
cultures incubated with thrombin, another mitogen for HF 
cells (23). The amount of PN in CM samples was measured 
by incubating '2sI-thrombin with CM for 1 h at 37"C, using 
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FIGURE  2  Effects  of  phorbol  ester,  EGF, and  thrombin  on  the 
cellular release of PN and plasminogen activator. Quiescent cultures 
of HF cells were incubated with  phorbol myristate acetate (PMA), 
EGF, or thrombin  (Th) at the concentrations shown  for  24  h.  PN 
and plasminogen activator in the culture media were then moni- 
tored, except in the case  of cultures treated with  thrombin. The 
medium  in  the  latter cultures  was  aspirated. The  cultures  were 
rinsed five times and incubated for 24 h with serum-free medium, 
which was then monitored for PN and plasminogen activator. In all 
cases, plasminogen activator activity was measured using the con- 
ventional fibrinolysis assay described in the legend for Fig. 1A. Cell 
number was measured with a Coulter Counter. The bars represent 
the range between duplicate determinations. 
SDS PAGE to resolve the SDS-stable  ~2sI-thrombin-PN com- 
plexes, and quantitating the complexes in a gamma counter. 
By this criterion, PN was present at 20-25 ng/ml in CM from 
control cultures,  up to 35 ng/ml in CM from thrombin-treated 
cultures,  up to 65 ng/mi in EGF-treated cultures,  and up to 
150 ng/ml in phorbol ester-treated  cultures (Fig. 2, A-C). 
Samples of the CM assayed  for PN were diluted into the 
standard fibrinolysis  well assay for PA activity.  As shown in 
Fig. 1, this assay indicated that CM from cultures treated with 
phorbol ester or EGF contained greatly increased levels of PA 
activity relative  to control cultures (Fig.  2,  E  and F).  CM 
from  cultures  incubated  with  thrombin  also  exhibited  in- 
creased PA activity (Fig. 2D). Although the fibrinolysis assay 
is only semiquantitative, comparison of the effects shown in 
Fig.  2  indicates  that  the  secretions  of PA  and  PN  were 
correlated  in  several  ways.  Each  of the  tested  factors that 
stimulated  PA release  also  stimulated  PN release.  For each 
factor, stimulation of both PA and PN occurred over approx- 
imately the same range of  factor doses. Thrombin significantly 
stimulated  PA  and  PN  secretion at  doses of 0.5  ~g/ml  or 
greater,  whereas phorbol ester  and EGF stimulated PA and 
PN secretion at doses >10 ng/ml and  1 ng/ml, respectively. 
(The implication of Fig. 2, C and F, that more phorbol ester 
was required for maximal PN release  than for maximal PA 
release  is misleading.  Fig.  2F does not portray an accurate 
dose-response curve for stimulation of PA release because CM 
from phorboi ester-treated  cultures caused  nearly complete 
fibrinolysis at all but the lowest phorbol ester dose.) Further- 
more, the rank order of potency of these factors for stimulat- 
ing PN secretion (phorbol ester > EGF > thrombin) paralleled 
their order of  potency for stimulating PA secretion. 2 Increased 
secretions  of PA and  PN were  not reflections  of a  general 
increase  in protein accumulation in CM of phorbol ester  or 
growth  factor-treated  cultures.  For  example,  total  protein 
concentration  in  serum-free  medium  of EGF-treated  and 
control cultures after 24 h was 12 +  3 ~g/ml and  14 _+ 4 lzg/ 
ml, respectively, according to the Bradford protein assay (24). 
Additionally, the amount of  collagen in 24-h CM from growth 
factor-treated  and  control  cultures  did  not  vary by >20% 
(data not presented). 
Thrombin, EGF, and phorbol ester all perturb cell growth 
regulation (23, 25, 26), indicating that PN secretion is sensitive 
to the growth state of the cells. In addition to being a mitogen, 
thrombin is also a serine protease,  suggesting that cells might 
regulate  PN secretion in  response to the presence of serine 
proteases.  However,  Table  I  shows that,  unlike  thrombin, 
neither urokinase, trypsin, chymotrypsin, nor elastase stimu- 
lated PN secretion.  Both urokinase and trypsin bind PN (15, 
27). Significantly,  of all the proteases  examined, only throm- 
bin is mitogenic for HF cells (reference  23 and our unpub- 
lished  data).  Thus,  PN  secretion was  not  stimulated  in  re- 
sponse to the presence of extracellular  protease activity per 
se, consistent with the possibility  that the stimulatory effect 
ofthrombin is accounted for by its mitogenic activity. 
2 In Fig. 2, after EGF or phorbol ester treatment the assays for PN 
and PA were carried out on the CM containing these factors, whereas 
after thrombin treatment the assays were carried out on thrombin- 
free medium conditioned by cultures that had been pretreated with 
thrombin. Assay of CM containing thrombin was not done because 
thrombin is fibrinolytic. The results shown in Fig. 2 were essentially 
unchanged when a parallel pretreatment protocol was used for all 
three agents (data not presented). 
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Inactive PA That Is Activated by Plasmin 
Because the standard fibrinolysis assay can cause activation 
of inactive PAs (1 1,  12,  14),  PA activity in CM was assayed 
directly by measuring conversion of ~2SI-plasminogen  to 125I- 
plasmin in the presence of plasmin inhibitors. This assay did 
not detect PA activity in CM from untreated cultures, or CM 
from cultures treated with phorbol ester or EGF (Fig.  3).  In 
view of our previous finding that CM from untreated HF cell 
TABLE  I 
Effect of Proteases on Cellular Release of PN 
Treatment  PN ng/106 cells  % Control 
None  49.5  100 
Thrombin  76.0  153 
Urokinase  32.1  65 
Elastase  52.2  105 
Chymotrypsin  31.2  63 
Trypsin  47.7  96 
Quiescent cultures of HF cells  were incubated with the indicated proteases 
at  I  v.g/ml,  or,  in  the  case  of trypsin,  0.4  ~tg/ml.  After  24  h,  the  culture 
medium  was  aspirated.  The cultures were  rinsed  five times and  incubated 
with serum-free  medium  for 24 h. The concentration of PN  in  this medium 
was measured.  Cell number, determined with a Coulter Counter, differed by 
<I 5% in all cultures. 
FIGURE  3  Effects  of  plasmin  and  PN  on  plasminogen activator 
secreted by HF cells treated with phorbol ester or EGF. Quiescent 
HF cells were incubated for 48 h with no supplement, EGF (10 ng/ 
ml),  or phorbol myristate acetate (10  ng/ml). The culture  media 
were acid-treated  as described for Fig. 1  C, and concentrated tenfold 
by ultrafiltration through an Amicon PM10  membrane. The media 
were diluted tenfold with 0.1  M  Tris-CI  buffer (pH 8.1) and again 
concentrated tenfold.  Aliquots  of  these  mixtures or  the  Tris-CI 
buffer were incubated for 20 min at 37°C, either with no addition 
(NA)  or with  plasmin at  0.2  ~.g/ml (P). Then,  bovine  pancreatic 
trypsin inhibitor (0.125 mg/ml), soybean trypsin inhibitor (0.1 mg/ 
ml), and 12Sl-plasminogen (0.2 mg/ml) were added with or without 
PN (1.0 #g/ml). After 10 h at 37°C the mixtures were solubilized in 
SDS sample buffer and heated in a boiling water both for 5 min. 
SDS PAGE was carried out by the method of Laemmli (37) in a gel 
containing a  5-20%  linear  gradient of  polyacrylamide, and  an 
autoradiogram was prepared. Lanes 1-3:  buffer; lanes 4-6: condi- 
tioned  medium from  untreated cultures;  lanes  7-9:  conditioned 
medium from cultures treated with EGF; lanes  10-12: conditioned 
medium from cultures treated with phorbol ester;  lane  13: buffer 
plus urokinase (0.75  CTA  U/ml). The arrows denote the 70- and 
26-kdalton chains  of plasmin. To increase  the visibility of the 26- 
kdalton bands, during printing the photograph was developed twice 
as long in this region (below the dashed line). 
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cultures  contains  inactive  PA  that  is  activated  by  plasmin 
(14), we measured PA activity in CM from phorbol ester or 
EGF-treated cultures when these media were pretreated with 
plasmin. Fig. 3 shows that CM from unsupplemented HF cell 
cultures contained detectable plasmin-activatable PA, as pre- 
viously described.  This material was present at an increased 
concentration in CM from EGF-treated cultures,  and at an 
even greater level in CM from phorbol ester-treated cultures. 
Thus, phorbol ester and EGF increased the secretion of the 
plasmin-activatable,  inactive  PA  that  was  also  released  in 
untreated  cultures.  When  CM  not pretreated  with  plasmin 
was incubated with  ~25I-plasminogen  at  37°C for prolonged 
periods (24 h or longer), small but detectable amounts of 125I- 
plasmin  were  occasionally generated  and  this  activity  was 
greatest in CM taken from cultures treated with phorbol ester 
or EGF  (data  not  presented).  It is  uncertain  whether these 
results  were  caused  by  very low  levels  of PA  activity that 
perhaps actually exist in CM or were caused by slow sponta- 
neous activation of inactive PA during the assay incubations. 
Inhibition of Plasmin by PN 
As shown in  Fig.  3, and previously (14),  PN inhibits  the 
plasmin-activated HF cell PA. If PN also inhibited plasmin it 
could inhibit fibrinolysis not only at the final proteolytic step 
but also at the level of activation of PA. The effect of purified 
PN on the fibrinolytic activity of plasmin is shown in Fig. 4. 
In the absence of added PN, plasmin at a concentration of 1 
x  l0  -8 M, as indicated by active site titration (28), hydrolyzed 
most  of the  JESI-fibrin  present  in  the  assay.  Purified  PN 
inhibited fibrinolysis by almost 90% at only 0. l0 ug/ml (2 x 
10  -9 M). 3 
Fig. 4  inset shows that  ~25I-plasmin (50 ng/ml; 5.6 x  10  -~° 
M) added to HF cell CM was taken into SDS-stable complexes 
with a medium component (lane 1). These complexes did not 
form when CM was pretreated  at pH 3 (lane 2).  Incubation 
of 125I-plasmin with purified PN resulted in the formation of 
~25I-plasmin-PN  complexes  that  were  the  same  molecular 
weight as the SDS-stable complexes formed in CM (lane 3). 
Urokinase  inhibited  formation  of complexes  between  ~25I- 
plasmin and PN (lane 4), suggesting that plasmin and uroki- 
nase compete for the same binding site on PN. 
DISCUSSION 
The  results  presented  above  show that  HF  cells  incubated 
with  agents  that  perturb  cell  growth  regulation  secrete  in- 
creased  quantities  of plasmin-activatable  PA  plus  PN,  an 
inhibitor  of both  HF  cell  PA  and  plasmin.  Previous work 
suggests that this  inactive  PA is  urokinase  proenzyme (14), 
and this has been supported by purification and preliminary 
characterization  (Eaton  and  Baker,  unpublished  results).  It 
3  The apparent  inhibition  of a  molar excess of plasmin  by PN  is 
inconsistent  with electrophoretic  and other evidence that PN forms 
irreversible l: l complexes with serine proteases ( 14, 15). It is possible 
that the actual concentration  of active plasmin  present in the assay 
was  less than  predicted,  either  because  of the  extreme  lability  of 
plasmin (29) or because a fraction of  plasmin that was reactive against 
the active site titrant  was unreactive  against  fibrin.  Moreover,  the 
concentrations of PN were determined  from a colorimetric assay (24) 
employing  a  serum  albumin  standard,  and  therefore  rest  on  the 
assumption that PN and serum albumin bind similar amounts of dye 
per milligram protein. FIGURE  4  Inhibition of plasmin by protease nexin. Plasmin (1.1 x 
10  -8 M) was incubated for 30 min at 37°C alone or with PN at the 
indicated concentrations in 0.1 M Tris-CI buffer (pH 8.1) containing 
0.1% BSA. The reaction mixtures (1 ml) were then incubated in 1251- 
fibrin-coated culture dishes for 4 h, and the radioactivity released 
into the buffer was measured in a gamma counter. The data show 
averages of duplicate determinations. Inset: 12Sl-plasmin  was incu- 
bated under the conditions described below and resolved by SDS 
PAGE (20) and autoradiography. Lane I: 12Sl-plasmin  (50 ng/ml) was 
incubated with  1 ml of medium conditioned by 48-h incubation 
with  quiescent  HF  cells.  Lane  2:  as  in  lane  1,  except that  the 
medium was pretreated at pH  3 as described in  Fig. 1C.  Lane 3: 
the plasmin was incubated with 0.1  #g of purified  PN  in culture 
medium. Lane 4: as in lane 3, except that urokinase (1 #g/ml) was 
present in the incubation mixture. Lane 5: 12Sl-plasmin. 
seems reasonable that secretion of HF cell PA as a proenzyme 
in the presence of PN (PA inhibitor) serves the same kind of 
regulatory function as does the coexistence of protease proen- 
zymes with protease inhibitors in blood: to confine proteolytic 
activity to a particular location or event. 
The precise function ofurokinaselike PAs released by fibro- 
blasts and many other normal cell types is unknown, but it is 
noteworthy that PA activity has been implicated in develop- 
mental processes that involve cell movement through tissues 
(30-32). The stimulation of HF cell PA proenzyme secretion 
by  mitogens  suggests  that  the  PA  plays  some  role  in  cell 
growth. 
Whether the  primary substrate  of urokinase in  tissues  is 
plasmin or some other protein  is unclear.  Recently,  Keski- 
Oja  and  Vaheri  (33)  showed  that  urokinase  cleaves a  66- 
kdalton human fibroblast extracellular matrix protein, result- 
ing in release of fibronectin from the matrix. Perhaps uroki- 
anse is protected from inhibition by PN when the protease is 
associated  with  a  site  on  the  extracellular  matrix  or  cell 
surface.  PN  would  then  focus  proteolytic activity at  these 
locations by inhibiting both soluble active PA and  plasmin 
generated  by active  PA.  Growing cells would  increase  PN 
secretion in  order to neutralize increased amounts of extra- 
cellular soluble PA. 
The activation of HF cell  PA by plasmin suggests  that its 
physiologic mode of activation also involves proteolytic cleav- 
age. As shown above, PN inhibits plasmin and so would limit 
this source of activation.  Release of PA  activity by SV  40 
virus-transformed  chick  fibroblasts  appears  to  involve  the 
action ofa chymotrypsin-like protease on the cell surface (34). 
It is possible that a  PN-insensitive protease capable of acti- 
vating HF cell PA is present on the surface of HF cells.  On 
the other hand,  our results have not provided any evidence 
that HF cell PA is activated in our cell culture system unless 
plasmin is present, so it is possible that the physiologic factors 
that activate this PA are not present in cell culture. 
The present results raise questions about data from standard 
fibrinolysis assays that suggest that phorbol ester or mitogens 
increase cellular production of PA activity. In the case of HF 
cell CM, this apparent effect is not shown by other assays for 
PA activity. Whether HF cell CM from treated or untreated 
cultures contains  any active PA  is  uncertain.  The  conven- 
tional fibrinolysis assay for PA involves dilution of CM into 
a buffer that facilitates activation of inactive PA (11,  12,  14) 
and as well decreases the concentration of PN. These effects 
provide a reasonable explanation for the indicated PA activity 
in HF cell CM and the apparently even greater PA activity in 
HF cell CM taken from cultures treated with phorbol ester or 
growth factors. Although dilution of CM dilutes the PA and 
PN equally, the PA (when activated) is a catalyst, so dilution 
only decreases its rate of reaction. PN, on the other hand, is 
a stoichiometric inhibitor (14) and its dilution decreases both 
the  rate at  which  it  reacts with  proteases and  the  absolute 
amount of protease it can  inhibit.  In the  fibrinolysis assay 
system this includes PA, plasmin generated during the fibri- 
nolysis assay, and any plasmin present initially as a contami- 
nanI in  the  plasminogen added  to  the  assay system.  It has 
been  proposed  that  initial  plasmin  contaminant  activates 
urokinase  proenzyme in  the  standard  fibrinolysis assay for 
PA activity (12). 
Several  reports  that  phorbol  ester  or  mitogen  treatment 
stimulates cellular PA activity have been based solely on data 
from  the  standard  fibrinolysis  assay  for  PA  activity  (e.g., 
references  1 and  22).  The present results suggest that these 
studies  need  to  be  reexamined.  However,  it  is  clear  that 
phorbol ester treatment does increase production of PA activ- 
ity by certain cell types (e.g., macrophages and Chinese ham- 
ster lung cells), at least when plaminogen is present (3, 6). In 
these cases, cells cultured on  ~251-fibrin clots in the presence 
of plasminogen  exhibit  greatly  increased  PA  activity  after 
phorboi  ester  treatment.  This  could  reflect  increased  cell- 
associated PA activity and not increased PA activity in CM. 
It will be worthwhile to determine whether HF cells attached 
to ~25I-fibrin-coated substrate exhibit a dramatically increased 
capacity to promote plasmin-mediated fibrinolysis when these 
cells are treated with phorbol ester or growth factors. It is of 
interest  that  phorbol  myristate acetate shifts the  molecular 
weight and  subcellular distribution  of PA  in  3T3  cells (35, 
36). 
The results presented here support the  view that  PN  is a 
key negative regulator of fibrinolytic activity in the extracel- 
lular  environment  of human  fibroblasts.  PN  is  the  major 
urokinase inhibitor secreted by HF cells, and therefore is the 
major inhibitor of activated HF cell PA (14). As shown above, 
PN also inhibits plasmin. Whether PN is the only significant 
plasmin inhibitor secreted by HF cells remains to be deter- 
mined. 
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